Search

In conversation with Charles Leclercq (ARxVision)

Julian Jackson (Founder and Director, VisionBridge) spoke to Charles Leclercq (CEO, ARx) about the ARxVision, a wearable device that captures the world around us through audio and artificial intelligence to empower blind and low-vision individuals. You can read the Eye...

The Story of Looking: Mark Cousins

Lake, Sweden, as featured in The Story Of Looking. In an interview with Director Mark Cousins about his relationship with sight and storytelling, Peter Cackett discusses Cousins’ recent film, The Story of Looking, and how its production informed, and was...

A paradigm shift in the way we approach cataract surgery

Cataract surgery is the most common elective surgical procedure in the UK [1], with in the region of 350,000 cases being conducted each year. With an ageing population, this figure will only continue to rise over time. Cataract surgery is...

An update on inherited retinal disorders (part 2): Approaches to therapy for IRDs

Part 1 of this topic can be found here There are currently no proven cures for inherited retinal disease (IRD). However, multiple avenues of research are being investigated to better understand disease mechanisms and trial potential therapies that may slow...

NICE drugs: an update on what’s good to go

Treatment options recommended by the National Institute for Health and Care Excellence (NICE) must be readily available for use in the NHS of England and Wales. This article provides an overview of recent guidance from NICE and summary advice issued...

Coming to terms with AI

A machine might be called intelligent if its response to questions could convince a person that it was human, a test proposed by Alan Turing in 1950 [1]. The author considers potential applications of artificial intelligence (AI) using machine learning...

Renewed momentum in ocular gene and cell therapy, broadening application to chronic disease

Gene and cell therapies offer the prospect of ground-breaking new avenues for the treatment of diseases, reflected in a renewed explosion of interest and investment in retinal gene therapy. Rod McNeil reports recent clinical trial readouts across a diverse range...

Update on emerging therapies for age-related macular degeneration

The 23rd European Society of Retina Specialists (EURETINA) Congress, held in Amsterdam, the Netherlands, provided a timely update on anti-complement therapy for geographic atrophy and emerging investigational therapies for neovascular age-related macular degeneration. Anti-complement therapy for geographic atrophy Geographic atrophy...